Wedbush analyst Robert Driscoll maintains $Revolution Medicines (RVMD.US)$ with a buy rating, and adjusts the target price from $70 to $67.
According to TipRanks data, the analyst has a success rate of 38.6% and a total average return of 2.7% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Revolution Medicines (RVMD.US)$'s main analysts recently are as follows:
The firm is updating its model following the company's completion of an upsized public offering of $862.5 million in common stock. Additionally, there remains notable potential for Revolution Medicines' RAS-ON platform, which could be enhanced either by the combination of two RAS-ON drugs or through integration with other treatments.
Revolution Medicines recently priced an offering to sell approximately 19M common shares plus 2.17M in pre-funded warrants at $46/share, raising gross proceeds of $862.5M. This followed additional data for RMC-6236 in non-small cell lung cancer, demonstrating an encouraging 38% overall response rate and 9.8 month-mPFS in median 3L RAS-mutant NSCLC patients. Analysts continue to believe that RAS(ON) inhibitors will transform standards of care in NSCLC, pancreatic ductal adenocarcinoma, and other RAS-mutant solid tumors, viewing the recent pullback in Revolution Medicines' stock as an attractive entry point.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
韋德布什分析師Robert Driscoll維持$Revolution Medicines (RVMD.US)$買入評級，並將目標價從70美元下調至67美元。
根據TipRanks數據顯示，該分析師近一年總勝率為38.6%，總平均回報率為2.7%。
此外，綜合報道，$Revolution Medicines (RVMD.US)$近期主要分析師觀點如下：
該公司正在更新其模型，因爲該公司已完成了一項總額爲86250萬美元的增資公開發行的普通股。此外，Revolution Medicines的RAS-ON平台仍然具有顯著潛力，這可以通過兩種RAS-ON藥物的組合或與其他治療方法的整合得到增強。
Revolution Medicines最近定價了一項出售約1900萬普通股和217萬預融資warrants的發行，價格爲46美元/股，籌集了86250萬美元的總收入。這是基於RMC-6236在非小細胞肺癌中的額外數據，顯示出令人鼓舞的38%的總體反應率和在中位數3L RAS突變NSCLC患者中的9.8個月 mPFS。分析師們繼續認爲，RAS(ON)抑制劑將改變NSCLC、胰腺導管腺癌和其他RAS突變實體瘤的標準療法，認爲Revolution Medicines股票的近期回調是一個有吸引力的入場點。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
